{"id":"bry812-for-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Rash"},{"rate":"5-15%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, BRY812 for injection blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively. This mechanism is thought to be responsible for the therapeutic effects of BRY812 for injection in the treatment of various types of cancer.","oneSentence":"BRY812 for injection is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:51:49.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07311538","phase":"PHASE2","title":"Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"BioRay Pharmaceutical Co., Ltd.","startDate":"2025-12","conditions":"Advanced Gynecological Malignancies","enrollment":56},{"nctId":"NCT06038058","phase":"PHASE1","title":"A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies","status":"RECRUITING","sponsor":"BioRay Pharmaceutical Co., Ltd.","startDate":"2023-10-10","conditions":"Advanced Malignancies","enrollment":164}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BRY812 for injection","genericName":"BRY812 for injection","companyName":"BioRay Pharmaceutical Co., Ltd.","companyId":"bioray-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BRY812 for injection is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}